VIB-UGent Medical Biotechnology Centre, VIB, Ghent, Belgium.
Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
PLoS One. 2022 Jan 31;17(1):e0262873. doi: 10.1371/journal.pone.0262873. eCollection 2022.
Influenza neuraminidase (NA) is implicated in various aspects of the virus replication cycle and therefore is an attractive target for vaccination and antiviral strategies. Here we investigated the potential for NA-specific antibodies to interfere with A(H1N1)pdm09 replication in primary human airway epithelial (HAE) cells. Mouse polyclonal anti-NA sera and a monoclonal antibody could block initial viral entry into HAE cells as well as egress from the cell surface. NA-specific polyclonal serum also reduced virus replication across multiple rounds of infection. Restriction of virus entry correlated with the ability of the serum or monoclonal antibody to mediate neuraminidase inhibition (NI). Finally, human sera with NI activity against the N1 of A(H1N1)pdm09 could decrease H6N1 virus infection of HAE cells, highlighting the potential contribution of anti-NA antibodies in the control of influenza virus infection in humans.
流感神经氨酸酶（NA）参与病毒复制周期的各个方面，因此是疫苗接种和抗病毒策略的一个有吸引力的靶点。在这里，我们研究了 NA 特异性抗体在原发性人呼吸道上皮（HAE）细胞中干扰 A（H1N1）pdm09 复制的潜力。小鼠多克隆抗 NA 血清和单克隆抗体可以阻断病毒进入 HAE 细胞的初始阶段以及从细胞表面的释放。NA 特异性多克隆血清也减少了多次感染的病毒复制。病毒进入的限制与血清或单克隆抗体介导的神经氨酸酶抑制（NI）的能力相关。最后，对 A（H1N1）pdm09 的 N1 具有 NI 活性的人血清可以降低 H6N1 病毒对 HAE 细胞的感染，突出了抗 NA 抗体在控制人类流感病毒感染中的潜在作用。
